Pfizer shelves Beqvez, a Spark Therapeutics developed product
Here's why a gene therapy product originally developed at CHOP spinout Spark Therapeutics was shelved by Pfizer.
The Pharma Letter21h
Pfizer’s Beqvez decision lays bare gene therapy challenges
US pharma giant Pfizer has ended all development and commercialization activities relating to fidanacogene elaparvovec, a ...
Making Gene Therapy Faster And Better With Fuse Vectors
Fuse Vectors has raised $5.2 million of funding as it moves closer to commercialising its innovative new approach to ...
Regeneron’s Gene Therapy Improves Hearing in Deaf Children
A gene therapy from Regeneron Pharmaceuticals Inc. improved hearing in nearly all deaf children in a clinical trial, results ...